Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

CANADA - 2025/05/11: In this photo illustration, the Rigetti Computing logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Rigetti Computing's stock jumped 30% on July 16 after reaching 99.5% gate fidelity on its 36-qubit modular system—halving error rates compared to its earlier 84-qubit chip. This achievement confirms their chiplet-based architecture as a scalable option for practica ...

PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.” Once granted, the patent will be in ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156859&from=4 CLASS PERIOD: June 22, 2023 to ...

Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseasesPLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target Inference from Spatialomics & Histology Using Multimodal AI & Phenotypes (TISHUMAP) project. This initiative w ...

Core Insights - Fifty1 AI Labs, LLC has announced a strategic partnership with the intent to acquire BioSpark AI Technologies Inc., aiming to revolutionize drug repurposing through advanced AI technologies [1][4] - The collaboration will integrate BioSpark's AI and large language model (LLM) platform with Fifty1 AI Labs' predictive modeling to enhance the analysis of extensive medical literature [2][3] Group 1: Partnership and Acquisition - The partnership is designed to leverage AI to extract transformative insights from medical literature, thereby advancing functional medicine and preventative care [1][4] - Fifty1 AI Labs intends to fully acquire BioSpark, which will enhance its capabilities in identifying promising drug repurposing candidates [3][4] Group 2: Technological Integration - BioSpark's proprietary AI platform automates the extraction and structuring of clinical data, which will significantly improve the efficiency of identifying therapeutic patterns [2][3] - The integration of BioSpark's capabilities with Fifty1 AI Labs' Bayesian inference and polypharmacy modeling will create a new approach to drug repurposing based on real-world clinical data [3][4] Group 3: Strategic Vision - The alliance aims to dominate preventative healthcare through personalized, data-driven strategies and rapid identification of drug candidates [4][5] - Both companies share a commitment to enhancing human expertise with ethical AI tools, focusing on opportunities in functional medicine that traditional trials may overlook [5][6] Group 4: Company Background - BioSpark AI Technologies Inc. specializes in organizing real-world clinical data using proprietary AI and LLM technologies and holds a U.S. patent for its automation system [6] - Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., focuses on AI-driven functional medicine, addressing critical needs in performance health and chronic disease prevention [7][8]

PHILADELPHIA, July 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket Pharmaceuticals” or the “Company”) for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses. Rocket Pharmaceuticals is headquartered in Cranbury, New J ...

Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3] Upcoming Financial Results - Vericel will report its second-quarter 2025 financial results on July 31, 2025, with a conference call and webcast scheduled for 8:30 a.m. ET [1] - The live webcast can be accessed through the Investor Relations section of the Vericel website, and a replay will be available until July 31, 2026 [2] Product Portfolio - Vericel markets three main products in the United States: - MACI: An autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3] - Epicel: A permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [3] - NexoBrid: A biological orphan product for eschar removal in burn patients, for which Vericel holds exclusive North American rights [3]

Core Insights - Royalty Pharma plc has appointed Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, enhancing its leadership team with expertise in biopharmaceuticals and finance [1][2][3] Group 1: Board Appointments - Carole Ho is the Chief Medical Officer and Head of Development at Denali Therapeutics, with 20 years of experience in biopharma, previously serving as Vice President of Clinical Development at Genentech [2][3] - Bess Weatherman has 35 years of experience as an investor in the healthcare industry and is currently a Special Limited Partner at Warburg Pincus, having joined the firm in 1988 [3] Group 2: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector, collaborating with various innovators [4] - The company has a portfolio that includes royalties on over 35 commercial products and 16 development-stage product candidates, indicating a strong position in the market [4] Group 3: Corporate Governance - The appointment of the new board members increases independent representation on the board to over 90%, reflecting Royalty Pharma's commitment to enhanced corporate governance [5]